Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers

Grann, Victor R.; Parsons, Ramon

doi:10.1001/jama.2011.1476

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These phenotypic characteristics have important implications for clinical trial design in EOC. If BRCA-status is not incorporated in clinical trials as a stratification factor or is not accounted for by preplanned statistical analysis then there is a significant risk for bias that may be introduced by unequal numbers of BRCA1/2-associated patients included in different study cohorts [38,101]. BRCA-status should be considered not only for clinical trials of PARPi or other drugs, but also in any clinical trial with a survival (PFS or overall survival) or chemosensitivity end point.…”

Section: Implications Of Brca-status For Clinical Trial Designmentioning

confidence: 99%

BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design

Konstantinopoulos¹,

Matulonis²

2013

Clinical Investigation

View full text Add to dashboard Cite

Despite significant advances in surgical and medical management, epithelial ovarian cancer (EOC) remains the fifth most common cause of cancer death and the most lethal of all gynecologic malignancies in the USA. Given that EOC is a genetically and biologically heterogeneous disease, a personalized approach to management based on recognition of different EOC subtypes with distinct genotypic and phenotypic characteristics may be an effective strategy to improve outcomes in this disease. EOC is characterized by frequent genetic and epigenetic alterations in gene members of the homologous recombination DNA-repair pathway, most commonly in the BRCA1 and BRCA2 genes. Germline BRCA1 and BRCA2 mutations have been identified in approximately 15% of all EOCs while an additional 30-35% of tumors harbor other genetic or epigenetic alterations in the homologous recombination pathway. In this review, we summarize the phenotypic characteristics of BRCA1/2-associated tumors and their clinical implications, both in terms of routine patient management as well as clinical trial design.

show abstract

Section: Implications Of Brca-status For Clinical Trial Designmentioning

confidence: 99%